Appointment of Interim Chief Financial Officer

Ondine Biomedical Inc.

28 March 2024

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Appointment of Interim Chief Financial Officer

Ondine Biomedical Announces the Appointment of Kwong Choo as Interim Chief Financial Officer

Ondine Biomedical Inc. (LON: OBI), the Canadian Life Sciences company pioneering light-activated antimicrobial treatments, announces the appointment of Kwong Choo as Interim Chief Financial Officer, following the resignation of previous CFO J. P. Errico.

Mr. Choo, CPA, CIMA, brings more than 15 years of experience in international public companies on NASDAQ, the Toronto Stock Exchange, and the TSX Venture Exchange, as well as with a number of private biotechnology and pharmaceutical companies. Mr. Choo has been working with Ondine since 2022.

Nikita Parkhaev CPA has been appointed as Vice President, Finance. Mr. Parkhaev most recently held the position of Controller at Ondine. Elaine Lei CPA has been appointed as corporate Controller; Ms. Lei previously held a management position at KPMG LLP.  

Additional appointments:

William (Bill) Kanz has been appointed as Senior Vice President, Engineering and Operations. In this role, Mr. Kanz will lead the engineering, operations and manufacturing teams, supporting Ondine's rapid commercial growth. Mr. Kanz is a certified quality engineer and lean six-sigma black belt, and brings a wealth of product management, manufacturing, and product development expertise to the company.  Building on his operational management capabilities, he has developed some of the world's leading atherectomy devices, ultrasound catheters and blood pumps, and has 47 patents to his name.

Caetano Sabino, Ph.D. has been appointed as Ondine's Director of Research and Development, building on his extensive pharmaceutical sciences background and many years of development of light-activated therapeutics.  Dr. Sabino is an expert in photodynamic disinfection, and has authored numerous important publications, textbooks, and patents in the field.  He most recently held the position of CEO, BioLambda, Científica e Comercial LTDA, Sao Paulo, Brazil manufacturing industrial equipment for light-based disinfection in hospitals, clinics, and the food industry.

Carolyn Cross, CEO, Ondine Biomedical commented.  "We will be providing an update on our upcoming dual priorities of continued significant commercial expansion and initiation of Phase 3 clinical trial in the USA with our partner, HCA Healthcare."

*ENDS*

Enquiries:

Ondine Biomedical Inc.
Angelika Vance, Corporate Communications	+001 [phone]
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Sam Butcher	[phone]
RBC Capital Markets (Joint Broker)
Rupert Walford, Kathryn Deegan	[phone]
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard	[phone]

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life science company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave®. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

 

END